This is a great indicator of how valuable an oral psoriasis drug with a strong safety profile can be. I also noticed that Allergan bought the dermatitis drug that failed in phase II as part of the deal. Given that we have several indications for B that are through Phase II successfully and will have a P phase II soon, this article provides comfort to me that Leo and Art are working on our best behalf in terms of value for the pipeline....al IMHO of course.